Prolactinoma

Prolactinoma is a benign, prolactin-secreting tumor of the anterior pituitary lactotroph cells and is the single most common functional (hormone-secreting) pituitary adenoma, accounting for roughly 40-50% of all clinically recognized pituitary adenomas.^[1] This chapter is a companion to, and deliberately does not repeat, the Galactorrhea chapter's extensive drug-induced and physiologic hyperprolactinemia differential — see that chapter for the antipsychotic, GI-dopamine-antagonist, and other medication-cause detail. Here the focus is the tumor itself: how a prolactinoma is distinguished from those other causes, the genuinely important microadenoma-versus-macroadenoma distinction and its implications for visual-field risk, cabergoline as the clearly preferred first-line dopamine agonist, the long-term cardiac-valve surveillance that distinguishes cabergoline from most other chronic oral therapies, the distinctive dopamine-agonist-withdrawal-trial concept, pregnancy-specific management, and surgical/radiation therapy for resistant or intolerant disease.

Prolactinomas are classified by maximum diameter on pituitary MRI: microprolactinoma (under 10 mm) and macroprolactinoma (10 mm or larger), with giant prolactinoma a further, much less common category for tumors exceeding 4 cm.^[1] Prevalence differs meaningfully by sex — approximately 10 per 100,000 in men versus 30 per 100,000 in women, with a peak incidence between ages 25 and 44^[1] — and, more clinically important, so does the size at presentation: about 90% of women are diagnosed with a microadenoma, while roughly 60% of men present with a macroadenoma, a disparity generally attributed to earlier symptom recognition in women (menstrual irregularity, galactorrhea) versus a more insidious, later-recognized presentation in men (low libido, erectile dysfunction, or mass-effect symptoms).^[1][2] This sex disparity is directly why a prolactinoma discovered in a man, or in a woman who is postmenopausal or otherwise without an obvious hormonal symptom to prompt earlier testing, carries a meaningfully higher pretest likelihood of macroadenoma-related mass effect and should be worked up accordingly.

Prolactin level as a rough guide to tumor size

Serum prolactin correlates, imperfectly but usefully, with prolactinoma size: concentrations in the range of roughly 100-200 mcg/L are typical for tumors under 1 cm, climbing to over 10,000 mcg/L for tumors over 3 cm.^[3][1] This relationship is useful in two directions — a very high prolactin level should prompt a search for a correspondingly large tumor on imaging, and, conversely, a large pituitary mass with an only mildly elevated prolactin should raise suspicion for a non-lactotroph mass (a non-functioning adenoma causing "stalk effect" hyperprolactinemia through disrupted dopamine delivery, rather than a true prolactin-secreting tumor) or for the hook-effect assay artifact discussed in the Galactorrhea chapter, which applies with particular force to a large mass alongside an unexpectedly modest reported prolactin.

Two distinct symptom clusters

Clinical presentation reflects two largely independent mechanisms, and recognizing which cluster (or both) a patient has directly shapes the workup:

• Hyperprolactinemia itself — through suppression of hypothalamic gonadotropin-releasing hormone pulsatility, prolactin excess produces hypogonadotropic hypogonadism in both sexes: oligomenorrhea, amenorrhea, or infertility in women; low libido, erectile dysfunction, and infertility in men. Galactorrhea can accompany either sex (see the Galactorrhea chapter for its own workup) but is a less reliable clue in men, in whom it is reported less often and less consistently recognized.^[1]
• Mass effect from the tumor itself — relevant almost exclusively to macroadenomas, and the reason this chapter treats size classification as clinically central rather than a lab curiosity. A macroadenoma can compress the optic chiasm, which sits directly superior to the pituitary gland, producing a classically bitemporal visual field defect as the decussating nasal retinal fibers are affected first; extension laterally into the cavernous sinus can compress cranial nerves III, IV, V1/V2, or VI, producing diplopia, ptosis, or facial numbness; and a large or rapidly expanding adenoma can cause headache independent of any chiasmal compression. Pituitary apoplexy — sudden hemorrhage or infarction into the adenoma — is an uncommon but genuine endocrine and neurosurgical emergency presenting with severe sudden headache, visual loss, ophthalmoplegia, and sometimes altered consciousness or hypopituitarism-driven hemodynamic instability; see Red Flags.

Because mass effect is size-dependent and hyperprolactinemia symptoms are not, a microadenoma essentially never causes visual field loss, while a macroadenoma can cause hypogonadism, mass effect, or both — which is the practical reason the micro/macro distinction, made on MRI, organizes the rest of this chapter's diagnostic and monitoring approach.

• Female sex and reproductive age for microprolactinoma; the great majority of women with a prolactinoma present with a microadenoma.^[1]
• Male sex carries a disproportionately higher likelihood of macroadenoma at diagnosis, reflecting delayed recognition rather than a difference in underlying tumor biology.^[1]
• Peak age of diagnosis 25-44 years, though prolactinoma occurs across the age spectrum, including in children and adolescents and in postmenopausal women (see Special Populations for both).^[1]
• Multiple endocrine neoplasia type 1 (MEN1) — prolactinoma is the most common functioning pituitary tumor seen in MEN1, and a family history of parathyroid, pancreatic-islet, or other pituitary tumors, or a personal history suggestive of primary hyperparathyroidism at a young age, should prompt consideration of an underlying genetic syndrome rather than assuming a sporadic tumor.^[2]
• No consistently identified modifiable lifestyle risk factor — unlike many other tumor types, prolactinoma has no established association with smoking, obesity, or other adjustable exposures that a pharmacist would counsel on for primary prevention.

Confirm true, non-physiologic, non-drug-induced hyperprolactinemia first

Before a prolactinoma is considered, the much more common physiologic and drug-induced causes need to be excluded — pregnancy, breastfeeding, and the extensive medication list (antipsychotics, metoclopramide/domperidone, and others) covered in full in the Galactorrhea chapter, along with primary hypothyroidism and renal failure. This chapter assumes that exclusion has been done, or is being done in parallel, and focuses on what follows once a pituitary cause is actually being considered.

Confirming the level and screening out artifact

• Normal prolactin is generally under about 25 mcg/L in women and under about 20 mcg/L in men.^[3]
• Draw the sample without recent nipple stimulation, breast examination, sexual activity, exercise, or significant acute stress, all of which can transiently elevate prolactin (see Galactorrhea).
• Mild, asymptomatic elevation (roughly 20-200 mcg/L) is frequently spurious. Current guidance is to repeat the prolactin measurement in 2-4 weeks, and at the same time test for macroprolactin — a larger, biologically inactive prolactin isoform (prolactin bound to immunoglobulin G, sometimes called "big-big prolactin") that is detected by standard immunoassays but has little to no clinical activity. Identifying macroprolactinemia explains the elevated result, is not itself clinically significant, and — importantly — can spare the patient further unnecessary investigation and imaging once it is confirmed.^[3] A pregnancy test (serum beta-hCG) belongs in this same round of testing for anyone of reproductive age.^[3]
• Marked elevation, generally over 200 mcg/L, in the absence of an interfering medication, is suggestive of a prolactinoma and is the threshold at which current Canadian guidance recommends referral to endocrinology.^[3]
• The hook effect — an immunoassay artifact producing a falsely low result when an extremely high true prolactin saturates the assay — is discussed fully in the Galactorrhea chapter; it is specifically relevant here because it is most often unmasked by finding a large pituitary mass on imaging alongside a normal or only modestly elevated reported prolactin, and is corrected by requesting a serial dilution.

Imaging

• Avoid neuroimaging in an asymptomatic patient with only mild hyperprolactinemia — this adds cost and risks turning up an incidental, clinically insignificant finding without changing management.^[3]
• Gadolinium-enhanced pituitary MRI is the gold-standard imaging test and is indicated for: marked hyperprolactinemia as above; any visual disturbance, extraocular movement abnormality, or new headache; hyperprolactinemia with no drug or other reversible cause identified after the workup above; or any other suspicion of hypopituitarism. Contrast-enhanced CT is an acceptable alternative when MRI is unavailable or contraindicated.^[3]
• Once a pituitary lesion is confirmed, classify it by maximum diameter as microadenoma (under 10 mm) or macroadenoma (10 mm or larger), and specifically document its relationship to the optic chiasm and cavernous sinuses — this classification drives both the urgency of ophthalmologic assessment and, later, eligibility for a dopamine-agonist withdrawal trial (see Monitoring & Follow-Up).^[1]

Completing the endocrine workup for a macroadenoma

• Formal visual field testing (perimetry) for any tumor abutting or compressing the optic chiasm on imaging, regardless of whether the patient has noticed a visual symptom.
• A broader anterior pituitary hormone panel — morning cortisol (with ACTH as indicated), free T4 and TSH, IGF-1, and gonadal hormones (LH, FSH, estradiol or testosterone) — for any macroadenoma, since a mass large enough to disrupt prolactin regulation can also compromise other pituitary axes through direct compression or stalk effect.^[1]

• Normalize serum prolactin and, with it, restore gonadal function and fertility where hypogonadism has suppressed them.
• Shrink the tumor and relieve or prevent mass effect — visual field compromise in particular should be treated as a genuine, non-negotiable treatment target, not a secondary consideration to biochemical normalization.
• Avoid indefinite, unnecessarily prolonged pharmacotherapy: unlike most other functioning endocrine tumors, a substantial minority of patients with a prolactinoma can successfully discontinue dopamine agonist therapy after a period of sustained control — see the withdrawal-trial discussion in Monitoring & Follow-Up — and building toward that possibility, rather than assuming lifelong therapy by default, is a genuine and distinctive feature of prolactinoma management.
• Minimize cumulative cardiac-valve exposure from long-term, higher-dose cabergoline through appropriate surveillance rather than either ignoring the risk or over-testing low-dose patients.
• Support safe pregnancy planning and management in a patient of reproductive age who wishes to conceive.
• Reserve escalation to surgery or radiation therapy for genuine dopamine-agonist resistance or intolerance, or for specific structural indications, rather than as an early-line option.
• Avoid treating a truly asymptomatic microprolactinoma with normal gonadal function purely because a tumor is present — see Choose Initial Treatment.

• Patient education on the two distinct symptom clusters (hypogonadism versus mass effect) so a patient understands why visual symptoms, in particular, need to be reported promptly rather than dismissed.
• Reinforce adherence counseling specific to cabergoline's once- or twice-weekly schedule — an easy regimen to under-dose if a patient assumes a "weekly" medication is less important to take consistently than a daily one; taking the dose with food reduces the nausea that is the most common reason for early discontinuation.
• Coordinate contraceptive counseling for a patient not currently planning pregnancy, since restored fertility is a genuine and sometimes unanticipated consequence of successful treatment.
• Bone-health counseling (adequate calcium and vitamin D intake, weight-bearing activity) for a patient with a period of untreated or inadequately treated hyperprolactinemia-driven hypogonadism — as in the Galactorrhea chapter, this bone density loss is not guaranteed to fully reverse with prolactin normalization alone.
• For observed (untreated) asymptomatic microprolactinoma, set and keep a defined periodic follow-up plan rather than open-ended "as needed" observation, so a change in symptoms, fertility plans, or a slowly enlarging tumor is actually caught.
• Psychosocial support around fertility concerns, sexual dysfunction, and, for a macroadenoma, the anxiety of an intracranial mass diagnosis — address these directly rather than only the biochemistry.
• For a patient on long-term higher-dose cabergoline, reinforce that the periodic cardiac surveillance discussed in Monitoring & Follow-Up is a routine, expected part of therapy rather than a sign that something has already gone wrong.

Pregnancy

Dopamine agonist therapy is generally discontinued immediately once pregnancy is confirmed, with two exceptions: a patient with an invasive macroadenoma, or one with ongoing pressure symptoms, in whom continued therapy may be needed.^[4] Management then diverges by tumor characteristics:

• Microadenoma — the risk of clinically significant enlargement during pregnancy is low (roughly 3% risk of any enlargement, under 2% risk of symptomatic growth).^[4] Discontinue the dopamine agonist, follow clinically every 2-3 months, and reserve MRI (without gadolinium) for a patient who develops symptoms (headache, visual change) rather than performing it routinely.
• Macroadenoma, intrasellar or not abutting the optic chiasm — discontinue the dopamine agonist on confirmation of pregnancy as with a microadenoma, but add formal visual field testing each trimester given the somewhat higher (though still modest) growth risk, and image only if symptoms develop.
• Large or extrasellar macroadenoma — growth risk during untreated pregnancy is substantially higher (on the order of 32% for an untreated macroadenoma, versus roughly 4.8% for one that has already been surgically debulked).^[4] Pregnancy is generally discouraged until definitive therapy (surgery or, less often, radiation) has reduced this risk; pre-pregnancy debulking surgery is often considered specifically to bring the symptomatic-growth risk down to under about 5%. If pregnancy occurs before definitive therapy, continued dopamine agonist therapy throughout pregnancy — restarting bromocriptine specifically if regrowth is confirmed — or, in advanced cases, second-trimester transsphenoidal surgery may be needed; this decision belongs with a specialist team.^[4]

Serial prolactin measurement during pregnancy is not useful and should not be routinely ordered — prolactin rises physiologically through gestation regardless of tumor behaviour, so a rising level does not reliably indicate tumor growth, and a stable or even falling level does not exclude it. Clinical symptoms and, when needed, visual fields and non-gadolinium MRI are the tools that actually track tumor status in pregnancy, not serial bloodwork.^[4]

Postpartum: check serum prolactin about 2 months after delivery and restart the dopamine agonist if it has returned to pre-treatment levels. For a patient who wishes to breastfeed, confirm tumor stability with MRI 4-6 weeks postpartum before deferring dopamine agonist restart, since breastfeeding itself does not appear to meaningfully increase the risk of tumor enlargement — but the dopamine agonist itself will suppress lactation if restarted, so timing this conversation before delivery matters.^[4] Remission — prolactin staying normal without medication after delivery — is seen in a meaningful proportion of patients: roughly 76% with prior nontumoral hyperprolactinemia, 70% with a microprolactinoma, and 64% with a macroprolactinoma in the largest reported series.^[4]

Choice of agent when actively planning pregnancy

Bromocriptine has historically been favoured when pregnancy is being actively attempted, reflecting its much longer track record — decades of experience and thousands of documented pregnancies with no signal for teratogenicity. Cabergoline's own first-trimester safety database has grown substantially, now exceeding 900 documented exposures with no increased risk of major malformation or spontaneous abortion identified, so this remains more a matter of accumulated clinical experience and practice convention than a proven safety difference between the two agents — worth knowing so a patient already stable and well-tolerating cabergoline is not automatically switched to a less-well-tolerated agent purely out of habit, without at least a specialist discussion.

Male patients

Men are more likely to present with a macroadenoma, both because galactorrhea is a less prominent and less monitored symptom in men and because low libido or erectile dysfunction is more often attributed to other causes before hyperprolactinemia is considered — a genuine contributor to delayed diagnosis rather than a difference in tumor biology.^[1] Once identified, the diagnostic and dopamine-agonist treatment approach is the same as in women; testosterone should be reassessed after prolactin normalizes; a persistently low testosterone despite normal prolactin needs its own separate workup rather than being assumed to simply lag behind.

Children and adolescents

Prolactinoma is uncommon but genuine in this age group and needs pediatric endocrinology involvement — growth deceleration, delayed or arrested puberty, and primary or secondary amenorrhea in an adolescent girl are the presenting clues to watch for, in addition to the adult symptom pattern.^[2]

Postmenopausal women

The absence of menstrual irregularity as a warning symptom means a prolactinoma in a postmenopausal woman is more likely to be found incidentally or after it has already grown — mirroring the male pattern above — which is a genuine reason to maintain a lower threshold for prolactin testing when other hyperprolactinemia symptoms (new galactorrhea, headache, visual change) are present in this group, even without menstrual clues to prompt it.^[2]

MEN1 and other genetic syndromes

A prolactinoma diagnosed in the setting of a personal or family history of primary hyperparathyroidism, pancreatic-islet tumors, or other pituitary tumors warrants referral for consideration of MEN1 genetic testing — prolactinoma is this syndrome's most common functioning pituitary tumor, and identifying MEN1 changes both the patient's own long-term surveillance plan and the counseling offered to at-risk relatives.^[2]

• During dopamine agonist titration, recheck prolactin roughly monthly until the dose is stabilized, then every 3-6 months once a normal level is sustained.
• Repeat pituitary MRI at about 3 months after starting therapy for a macroadenoma to confirm the expected shrinkage, then at longer intervals (for example, annually) once a clear treatment response is established; a microadenoma being actively treated for symptom control generally needs less frequent imaging once prolactin has normalized.
• Continue periodic formal visual field testing for any tumor that was abutting or compressing the optic chiasm at diagnosis, until imaging confirms adequate shrinkage away from the chiasm.
• Cardiac valve surveillance on cabergoline — obtain a baseline transthoracic echocardiogram before starting therapy. For a patient on 2 mg/week or less, repeat echocardiography at 5 years, and continue at 5-yearly intervals if unchanged; for a patient on more than 2 mg/week, echocardiography is recommended annually. If a change in valve function is found in a patient on 2 mg/week or less, move that patient to annual echocardiography if treatment continues; a finding of mild-to-moderate regurgitation alone, without a structural leaflet change, should not automatically trigger stopping therapy — decisions to discontinue medication on the basis of an echocardiographic finding should be made only after review by an echocardiographer experienced in drug-induced valvulopathy.^[5] An annual clinical cardiovascular examination, including listening for a new murmur, is a reasonable adjunct between echocardiograms for any patient on long-term therapy.^[5] No further echocardiography is needed after a patient stops cabergoline, provided no moderate or severe valve abnormality was ever identified.^[5]
• Dopamine agonist withdrawal trial — unlike most other functioning endocrine tumors, a genuine, guideline-recognized subset of patients can successfully discontinue therapy long-term. The criteria established by the landmark prospective study in this area, and still the framework most guidance is built around, are: normal prolactin on treatment; no visible tumor remnant on MRI, or at least 50% shrinkage with the remaining tissue at least 5 mm from the optic chiasm and no cavernous sinus invasion; and typically at least 2 years of treatment before the attempt.^[6] Counsel explicitly that recurrence after a supervised withdrawal attempt is genuinely common, not a sign that something went wrong: in the largest reported cohort, recurrence over 2-5 years of follow-up occurred in 24% of patients originally diagnosed with nontumoral hyperprolactinemia, 31% with a microprolactinoma, and 36% with a macroprolactinoma.^[6] Reassuringly, renewed tumor growth was not observed in any patient who recurred biochemically in that cohort, but gonadal dysfunction did redevelop in a meaningful proportion of those who recurred, which is why a defined recheck schedule after stopping — not just at the moment of stopping — is essential.^[6] If prolactin rises again, resume dopamine agonist therapy rather than repeating a second withdrawal attempt shortly afterward.
• Document tumor size trend, current dopamine agonist dose and cumulative exposure, and echocardiography due dates clearly at each visit — the cumulative-dose tracking in particular is easy to lose across multiple prescribers and years of refills, and is exactly the kind of longitudinal detail a pharmacist is well positioned to flag.

1. Inadequate response to cabergoline despite an adequately titrated dose (up to 2 mg/week, occasionally higher under specialist supervision) and confirmed adherence: consider switching to bromocriptine, though cross-resistance is common since both agents share the same mechanism.
2. True resistance — inadequate prolactin normalization and inadequate tumor shrinkage despite maximally tolerated doses of both agents — or genuine intolerance to both: refer for transsphenoidal surgical evaluation. Reported remission rates are meaningfully higher for microadenoma than macroadenoma (on the order of roughly 85-90% versus roughly 55-60% in surgical series from experienced pituitary centres), which is worth setting as a realistic expectation before referral, particularly for a large or invasive macroadenoma.^[2][1]
3. Persistent or worsening visual field defect despite adequate dopamine agonist dosing and confirmed adherence: do not continue to escalate the medical dose indefinitely — refer urgently for surgical evaluation given the time-sensitive nature of visual pathway compromise.
4. Genuine surgical and medical resistance/intolerance, an unresectable or recurrent tumor, or an aggressive/malignant prolactinoma: radiation therapy (stereotactic radiosurgery where tumor geometry and distance from the optic apparatus allow, or fractionated external-beam radiotherapy otherwise) is the next option, understanding that its prolactin-lowering effect is delayed, sometimes by years, and that hypopituitarism affecting other pituitary axes is a real long-term risk requiring its own ongoing surveillance.^[2]
5. Recurrence after a supervised dopamine-agonist withdrawal trial: resume therapy at the previously effective dose rather than repeating the withdrawal attempt shortly afterward; reassess eligibility for a further attempt only after another sustained, adequately long period of control.^[6]
6. New or worsening red-flag findings at any point in follow-up, even in a patient previously stable for years: treat as a new presentation (repeat imaging, reassess the whole pituitary axis) rather than assuming simple, expected progression of known disease.

• Treating every incidentally discovered microprolactinoma with a dopamine agonist by default — a truly asymptomatic microprolactinoma with normal gonadal function is a genuine candidate for observation rather than automatic treatment.
• Missing that a large pituitary mass with only a modestly elevated prolactin may reflect the hook-effect assay artifact rather than a non-prolactin-secreting tumor, and failing to request a diluted sample.
• Ordering routine serial prolactin levels during pregnancy to monitor tumor status — the level rises physiologically and does not reliably reflect tumor behaviour; clinical symptoms and visual fields, not bloodwork, are what should be tracked.
• Skipping baseline and appropriately scheduled echocardiography for a patient on higher-dose or long-duration cabergoline, or, at the other extreme, over-testing a stable, low-dose (2 mg/week or less) patient more often than the evidence supports.
• Never raising the possibility of a supervised dopamine-agonist withdrawal trial with an eligible, long-term stable patient, and instead defaulting to indefinite therapy without revisiting the question.
• Assuming a recurrence after a withdrawal trial reflects a management failure rather than counseling for it in advance as a genuinely expected possibility.
• Continuing to escalate the dopamine agonist dose indefinitely in a patient with a persistent visual field defect instead of escalating the referral.
• Forgetting that a macroadenoma can compromise pituitary axes other than prolactin, and treating an elevated prolactin in isolation without a broader anterior pituitary hormone panel.
• Restarting a dopamine agonist immediately postpartum in a patient who wants to breastfeed without first discussing that it will suppress lactation, and without confirming tumor stability first.
• Overlooking a family or personal history suggestive of MEN1 in a patient with a new prolactinoma diagnosis.
• Confusing this chapter's tumor-specific content with the Galactorrhea chapter's drug-cause workup — a patient on a causative antipsychotic with a normal pituitary MRI does not have a prolactinoma, and should be managed per the Galactorrhea chapter's medication-focused pathway instead.

How to use this table: doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment and pregnancy status. Select any drug name to open its complete Pharmasist Drug Database page.

Dopamine Agonist Therapy — Prolactinoma

First-line pharmacotherapy for a symptomatic microprolactinoma or any macroprolactinoma requiring treatment. Not required for a truly asymptomatic microprolactinoma with normal gonadal function, which is a reasonable candidate for observation instead.